HER2-directed therapy

February 28, 2020March 23, 2020

FDA Approves Nerlynx-Capecitabine Combo for HER2-positive Metastatic Breast Cancer

News

Nerlynx (neratinib) is now approved in the U.S. for use, in combination with capecitabine, to treat HER2-positive breast cancer patients who have received two or more HER2-targeted therapies for their metastatic ... Read more

August 1, 2016August 1, 2016

Number of HER2-positive Breast Cancers Double Under New Testing Guidelines

News

The American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) changed the guidelines that determine which breast cancers are considered HER2-positive in 2013. According to a recent study from the Mayo ... Read more